Hepadnaviridae infectious disease

This phase 2 trial is testing whether a combination of two experimental drugs, BRII-835 and BRII-179, can clear the hepatitis B virus from the body in adults with chronic infection. Participants will receive the drug combination and then be monitored to see if they can safely sto…

Researchers are testing a new vaccine called LBVD that combines protection against diphtheria, tetanus, whooping cough, hepatitis B, polio, and Hib into a single injection. The study will enroll healthy infants aged 6 to 8 weeks, who will receive three doses at 6, 10, and 14 week…

This study tests a hexavalent vaccine that protects against six diseases, including polio, but uses a lower dose of the inactivated polio vaccine (IPV). The goal is to see if this reduced-dose version works as well as the standard full-dose vaccine in infants. Around 1,500 health…

This early-stage trial tested a new two-part vaccine designed to treat chronic hepatitis B. It involved 26 healthy adults to check safety and immune response. The vaccine uses a protein first shot followed by a booster to teach the immune system to attack the virus.

This study tested whether a double-dose hepatitis B vaccine (40 micrograms) works better than the standard dose (20 micrograms) in people with HIV who did not respond to earlier hepatitis B shots. The goal was to see if the stronger dose could help their immune system produce eno…

This study tested three different ways of giving the hepatitis B vaccine to 437 people with HIV whose CD4 counts were above 200. The goal was to see which schedule—standard dose, double dose, or skin injections—works best to protect them from hepatitis B, a virus that can cause s…

This completed study checked the safety of the Hexaxim vaccine in 713 infants aged 2 months and older in South Korea. Researchers tracked side effects like injection site reactions, fever, and crying after routine vaccination. The goal was to confirm the vaccine's safety in every…

This study looked at whether giving young children 2 doses of the hepatitis B vaccine works as well as the usual 3 doses. Over 400 children aged 2 to 18 months took part. Researchers measured blood antibody levels to see if fewer shots still provide strong protection against the …

This early-stage study tested a new hepatitis B vaccine that includes an experimental booster called AS37. The goal was to see if the vaccine is safe and how well it triggers the immune system. 122 healthy adults aged 18-45 received two doses one month apart. Researchers monitore…

This study tested a new combination vaccine called Shan6™, which protects against six diseases (diphtheria, tetanus, whooping cough, hepatitis B, Hib, and polio) in healthy infants and toddlers in Thailand. The trial involved 460 participants and compared Shan6™ to a similar 5-in…

This study tests a new drug called AHB-137 in 86 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if AHB-137 can clear the hepatitis B surface antigen from the blood, which would mean the virus is under control and patients might be …

This early-stage trial tests an experimental vaccine called VRON-0200 in adults with chronic hepatitis B who are already taking antiviral medication. The vaccine aims to boost the body's immune response against the virus. Some participants also receive two additional drugs, elebs…

This study tests a drug called hydronidone in 300 adults with liver scarring (fibrosis or cirrhosis) from chronic hepatitis B. Participants take the drug three times daily for 28 days to see if it is safe. The main goal is to track any side effects.

This study tests a drug called hydronidone in 200 adults with liver fibrosis caused by chronic hepatitis B or fatty liver disease. Participants take three capsules three times daily for 28 days. The main goal is to check for side effects, not to measure how well the drug works.

This study tests a drug called hydronidone in 150 adults with liver scarring caused by chronic hepatitis B. Participants take the capsules three times daily for 28 days. The main goal is to check for side effects and ensure the drug is safe. This is an early-phase trial, so it fo…

This study tests whether adults with chronic hepatitis B who have no liver scarring can safely stop taking antiviral drugs. The 140 participants have undetectable virus levels and negative HBeAg status. Researchers will monitor for viral relapse and liver problems over time.

This early-phase trial tested an experimental drug called BW-20507 in 32 people. First, healthy volunteers received a single dose to check safety. Then, people with chronic hepatitis B received multiple doses to see how the drug behaves in the body and whether it fights the virus…

This phase 2 trial is testing whether adding an experimental drug called JNJ-73763989 to standard oral antivirals can better suppress hepatitis D virus in people who are also infected with hepatitis B. About 52 adults with stable chronic co-infection will receive either the combi…

This study tests a care model where hospitalized adults with opioid use disorder and a serious infection receive long-acting injectable buprenorphine from their infectious disease doctors, alongside infection treatment. The goal is to keep patients on effective medication for opi…

This Phase 3 study tests bepirovirsen, an experimental drug, in 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough to allow patients to stop all hepatitis B treatments and remain viru…

This Phase 3 trial tests a drug called bepirovirsen in nearly 1,000 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough that participants can safely stop all hepatitis B medications and re…

This study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…

This early-stage study tested a new treatment approach for adults with chronic hepatitis B or D. Twenty participants received two medications in sequence: P1101 (a type of interferon) followed by an anti-PD1 drug. The main goal was to check safety and tolerability, while also loo…

This completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver …

This Phase 2 trial tested an oral drug called selgantolimod in 29 adults with both chronic hepatitis B and HIV. Participants had been on stable antiviral therapy for both viruses for at least 5 years. The study aimed to see if the drug is safe and can lower hepatitis B surface an…

This study tests an experimental drug called AHB-137 in healthy volunteers and people with chronic hepatitis B who are already on antiviral medication. The goal is to check if the drug is safe and shows early signs of controlling the virus. About 129 participants will receive eit…

This completed Phase 3 trial tested a once-daily combination of two drugs, lonafarnib and ritonavir, in 10 adults with chronic hepatitis D. The goal was to see if the regimen is safe and can lower the amount of virus in the blood over 48 weeks of treatment and 24 weeks of follow-…

This phase 2b trial tested a combination of two experimental vaccines (VTP-300) plus a low dose of the cancer drug nivolumab in 121 adults with chronic hepatitis B who were already on antiviral medication. The goal was to see if the treatment could significantly lower hepatitis B…

This Phase 2 study tested an experimental drug called AB-729 combined with pegylated interferon and standard antiviral pills in 43 adults with chronic hepatitis B. The goal was to see if this approach could safely lower hepatitis B surface antigen levels and allow some participan…

This study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on ant…

This study tested an experimental drug called VIR-2218 in 84 adults with chronic hepatitis B. Some participants received VIR-2218 alone, and others got it combined with pegylated interferon. The main goals were to check safety and how well the drug works against the virus. The st…

This early-stage trial tests AB-101, an oral drug that blocks a protein called PD-L1 to help the immune system fight the hepatitis B virus. The study involves 128 people, including healthy volunteers and patients with chronic hepatitis B. Researchers are primarily checking for sa…

This study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …

This early-stage trial tested an experimental injection called HH-006 in 36 adults with untreated chronic hepatitis B. The study aimed to check the drug's safety, how the body processes it, and whether it can lower virus levels. Participants received either HH-006 or a placebo ov…

This study tests whether a DNA vaccine can help people with chronic hepatitis B control the virus after they stop taking standard antiviral drugs. The vaccine aims to boost the immune system to delay the virus from becoming active again. The trial involves 70 adults who have unde…

This study tested the drug eltrombopag in 48 Chinese adults with chronic hepatitis B and a bleeding disorder called immune thrombocytopenia (low platelets). The goal was to see if taking eltrombopag for 6 to 22 weeks could safely raise platelet counts. The trial is complete, but …

This early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The s…

This study tested a new drug called TQA3605 in 122 adults with chronic hepatitis B who still had low levels of virus despite standard treatment. Participants took either TQA3605 or a placebo alongside their usual antiviral pills for 24 weeks. The goal was to see if adding TQA3605…

This early-stage trial tested two experimental therapeutic vaccines, GS-2829 and GS-6779, in 83 healthy people and those with chronic hepatitis B. The main goal was to check safety and tolerability, while also measuring immune responses. The vaccines are designed to help the body…

This completed phase 2 study tested a two-step treatment for chronic hepatitis B. First, participants received an antisense drug (bepirovirsen) for 12 or 24 weeks, followed by a targeted immunotherapy. The goal was to see if this sequence could safely improve virus control beyond…

This study tested an experimental injection called RBD1016 in 48 adults with chronic hepatitis B who were already taking standard antiviral pills. The goal was to see if the injection could safely lower hepatitis B surface antigen (HBsAg), a marker of the virus. Participants rece…

This study tested whether adding pegylated interferon alfa-2a to standard nucleoside analogue therapy could help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg). 119 adults with HBeAg-negative chronic hepatitis B who had been on nucleoside analogues f…

This early-stage trial tests an experimental oral drug called ALG-000184 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it can lower hepatitis B virus levels. Participants take the drug d…

This study tested an experimental drug called ARO-HBV in healthy volunteers and people with chronic hepatitis B. The drug uses RNA interference to try to stop the virus from multiplying. The main goal was to check safety and how the body processes the drug, not yet to prove it wo…

This early-stage trial tested a DNA vaccine in 10 adults with chronic hepatitis B who had not responded to standard treatments. The vaccine was designed to train the immune system to fight the virus. The main goal was to check safety, with a secondary goal of seeing if the vaccin…

This study tested several new drug combinations in 281 people with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if adding experimental drugs could clear a key virus marker (HBsAg) from the blood. Participants received different combinati…

This completed Phase 4 trial tested a herbal supplement called AntiCov-220 in 82 people with underlying health conditions, including HIV and cancer. The goal was to see if it could prevent and treat COVID-19 by boosting the immune system and fighting the virus. The study compared…

This study checked how well new blood tests (Access HBV assays) can detect hepatitis B infection. Researchers tested over 21,000 leftover blood samples from adults, including blood donors and hospital patients. The goal was to see if these tests are accurate compared to existing …

This study tested a strategy of using rapid, point-of-care diagnostic tests for sexually transmitted infections (STIs) in pregnant women attending antenatal clinics in Zimbabwe. Over 1,000 women were offered testing for chlamydia, gonorrhea, trichomoniasis, syphilis, and hepatiti…

This trial asks whether giving dialysis patients four doses of a double-strength hepatitis B vaccine offers better protection than the standard three doses. People with kidney failure on dialysis often respond weakly to vaccines, leaving many unprotected. The study will compare a…

This trial tests whether a three-dose hepatitis B vaccine can protect healthcare workers in Zambia from infection. The vaccine is given at 0, 1, and 6 months, and blood tests measure the immune response. The goal is to see if the vaccine produces protective antibodies and cellula…

This study tested whether giving pregnant women with hepatitis B a daily pill (tenofovir) plus giving their newborns a hepatitis B vaccine at birth could safely prevent the virus from passing to the baby. The trial enrolled 317 women in the Democratic Republic of Congo and follow…

This early-phase study tests whether anakinra, a drug that blocks inflammation, can make the heart more sensitive to inotropes (medicines that strengthen heart contractions) in people with end-stage heart failure. If successful, patients might need lower, safer doses of inotropes…

This study tested two simple methods—mechanical vibration and flick tapping—to reduce pain in 80 infants receiving their second hepatitis B vaccine. Babies were randomly assigned to one of the two techniques, and researchers measured pain scores, crying time, and vital signs. The…

Researchers are surveying people in Thailand who have chronic hepatitis B to find out how many also carry hepatitis D, a virus that can make liver disease worse. The study focuses on groups at higher risk, including people who inject drugs, men who have sex with men, prisoners, a…

This study looked at 805 blood donors who tested positive for hepatitis C virus (HCV) to learn how the virus spreads and affects health over time. Researchers collected blood samples and health information to track infection and liver disease. The goal was to better understand HC…

This observational study follows people with hepatitis B-related acute-on-chronic liver failure who receive one of three antiviral drugs: entecavir, tenofovir alafenamide, or tenofovir amibufenamide. Researchers measure two newer virological markers, HBV RNA and HBcrAg, over time…

This early study tests a single dose of the drug pevifoscorvir in 30 people with chronic hepatitis B, some with kidney problems and some with healthy kidneys. Researchers want to see how kidney function affects drug levels and safety. The goal is to learn how to dose the drug pro…

This early-stage study tests a single dose of the drug pevifoscorvir sodium in 16 adults: 8 with moderate liver impairment and 8 healthy volunteers. Researchers want to see how the drug is processed in the body and if it is safe. The goal is to gather information for future dosin…

This early-stage trial will test a new drug called hydronidone, which is being developed for liver fibrosis caused by hepatitis B. Since patients often need to take antiviral drugs for hepatitis B, researchers want to see if hydronidone can be taken safely alongside four common a…

This study looks back at the medical records of 1,000 adults with both chronic hepatitis B and metabolic fatty liver disease. The goal is to understand how these conditions affect kidney function, especially in people on long-term antiviral therapy. Researchers will also examine …

This study tested whether people with chronic hepatitis B who had been on antiviral drugs for at least 4 years could safely stop treatment. Fifteen adults were monitored with monthly blood tests for 6 months after stopping, then every 3 months. The goal was to see if the virus st…

This study examines whether long-term use of antiviral drugs for chronic hepatitis B is linked to kidney problems in patients who also have non-alcoholic fatty liver disease. Researchers will analyze medical records from 300 patients to compare kidney function among those taking …

This study investigates whether a single dose of bepirovirsen, a potential treatment for hepatitis B, affects the heart's electrical activity. Healthy adults aged 18 to 55 receive either the drug or a placebo, and their heart rhythms are monitored continuously by ECG. The goal is…

This study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …

This study looks at how certain genetic changes (mutations) in the hepatitis B virus (HBV) affect the amount of virus in the blood of people with chronic infection. Researchers analyzed blood samples from 92 patients not on antiviral treatment. They found that specific mutations …

This study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…

This study followed 250 chronic hepatitis B patients over age 30 who had detectable virus but normal liver enzyme levels (ALT). All had never received antiviral treatment before. Researchers measured how many became virus-negative after 48 weeks of antiviral therapy, and how many…

This study looked at how many people with cirrhosis in French general hospitals were vaccinated against diseases like hepatitis, flu, and COVID-19. Researchers surveyed 742 patients to see if they were up to date on their shots. The goal was to find gaps in vaccination coverage s…

This study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…

This study looked at how factors like chronic stress and depression might speed up liver damage in Korean Americans with chronic hepatitis B. Researchers followed 365 participants over time, collecting health records, hair samples, and interview data. The goal was to understand w…

This study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…

This completed study looked at 274 foreign-born adults in the US with chronic hepatitis B to understand why many do not get proper follow-up care. Participants completed a one-time survey about their background, immigration experience, and healthcare access. The goal is to identi…

This study looked at over 5,000 adults in Zambia to find out how many have hepatitis B and how many need treatment. Researchers tested people in their homes and then did more tests on those who tested positive. The goal was to gather information, not to test a new treatment or cu…

This study looked at how many medical students have immunity against hepatitis B and varicella-zoster (chickenpox) viruses. Researchers tested 401 students to see their protection levels and vaccination rates. The goal was to understand if current immunization programs are workin…

This study tested 350 detainees in Nîmes, France for HIV, hepatitis B, and hepatitis C using rapid diagnostic tests. Many detainees come from areas where these infections are common and often don't know their status. The goal was to find out how many are infected so that care can…

This completed study looked at 217 adults with chronic hepatitis B to see how common fatty liver and fatty pancreas are in obese versus lean patients. Researchers used ultrasound and a special liver stiffness test to measure fat and scarring. The goal was to learn more about how …

This study looked at human proteins that stick to hepatitis B virus particles in blood samples from 14 infected adults. The goal was to identify these proteins and understand how they help the virus survive and spread. This is basic research, not a treatment, but it may point tow…

This completed study looked at whether COVID-19 patients treated with steroids might have a reactivation of hepatitis B virus (HBV). Researchers followed 1,793 hospitalized adults who needed oxygen and received steroids for COVID-19 pneumonia. The goal was to see how well doctors…